Compare NODK & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NODK | PRQR |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 302.0M | 262.5M |
| IPO Year | 2016 | 2014 |
| Metric | NODK | PRQR |
|---|---|---|
| Price | $14.83 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.78 |
| AVG Volume (30 Days) | 26.1K | ★ 695.8K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $285,050,000.00 | N/A |
| Revenue This Year | N/A | $8.25 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.37 | $1.33 |
| 52 Week High | $16.70 | $3.10 |
| Indicator | NODK | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 29.67 |
| Support Level | $13.00 | $1.51 |
| Resistance Level | $15.64 | $1.58 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 23.48 | 0.00 |
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.